parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
Published 4 years ago • 189 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
2:33
interim analysis of add-on parsaclisib in myelofibrosis with suboptimal ruxolitinib response
-
2:06
parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
1:21
phase iii trial of ruxolitinib plus parsaclisib in treatment-naïve myelofibrosis
-
1:01
phase i study of ruxolitinib plus abemaciclib for patients with myelofibrosis
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:54
ruxolitinib in the real world: myelofibrosis
-
14:40
primary myelofibrosis (pmf)
-
1:30:33
lecture 11 - the myelocytic series
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
3:49
manifest: pelabresib (cpi-0610) ruxolitinib in advanced myelofibrosis patients
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
3:21
manifest: ruxolitinib plus pelabresib for jak-inhibitor naïve myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:10
management of ruxolitinib failure in myelofibrosis
-
2:55
novel combinations with ruxolitinib being investigated for myelofibrosis
-
1:27
bet inhibitor pelabresib (cpi-0610) and ruxolitinib for myelofibrosis